LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for
… ProQR traite le premier patient dans l’essai STELLAR de Phase … CAMBRIDGE, Massachusetts, 11 mars 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq : PRQR), société consacrée à … STELLAR examinera si le QR-421a (traitement par ARN de ProQR) peut ralentir la progression de la maladie, voire …
… ProQR Reaches Agreement with the FDA on Design of Phase 2/3 … & CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Executive Vice President of Research and Development of ProQR. “Our regulatory discussions have been very …
… ProQR Announces Positive Findings From an Interim Analysis in … pandemic expected to impact timelines for the pipeline ProQR anticipates its cash runway will fund operations into … Executive Vice President of Research and Development of ProQR. “We are pleased with the current safety profile and …
… ProQR Announces an Investor and Analyst Event and … LEIDEN, Netherlands, Oct. 1, 2015 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that … information or to RSVP, please contact Sariette Witte at ir@proqr.com . OTS The abstract titled: 'QR-010 penetrates …
… ProQR Announces an Investor and Analyst Event and … LEIDEN, Netherlands, April 25, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) today announced that … molecule that will move into clinical development using ProQR’s RNA approach. ARVO The p.Cys998X mutation which is a …
Presentation at the 18th International Symposium on Retinal Degeneration (RD2018) at 8:30 am GMT on Sept. 5th Investor conference call to be held at 8:15 am ET on Sept. 5th